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Early Phase Pharmacokinetics but Not Pharmacodynamics
Are Influenced by Propofol Infusion Rate
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Background: Conventional compartmental pharmacokinetic
models wrongly assume instantaneous drug mixing in the cen-
tral compartment, resulting in a flawed prediction of drug dis-
position for the first minutes, and the flaw affects pharmaco-
dynamic modeling. This study examined the influence of the
administration rate and other covariates on early phase kinetics
and dynamics of propofol by using the enlarged structural
pharmacokinetic model.
Methods: Fifty patients were randomly assigned to one of five
groups to receive 1.2 mg/kg propofol given with the rate of 10
to 160 mg · kg1 · h1. Arterial blood samples were taken
frequently, especially during the first minute. The authors com-
pared four basic pharmacokinetic models by using presystemic
compartments and the time shift of dosing, LAG time. They also
examined a sigmoidal maximum possible drug effect pharma-
codynamic model. Patient characteristics and dose rate were
obtained to test the model structure.
Results: Our final pharmacokinetic model includes two con-
ventional compartments enlarged with a LAG time and six pr-
esystemic compartments and includes following covariates:
dose rate for transit rate constant, age for LAG time, and weight
for central distribution volume. However, the equilibration rate
constant between central and effect compartments was not
influenced by infusion rate.
Conclusions: This study found that a combined pharmacoki-
netic-dynamic model consisting of a two-compartmental model
with a LAG time and presystemic compartments and a sigmoi-
dal maximum possible drug effect model accurately described
the early phase pharmacology of propofol during infusion rate
between 10 and 160 mg · kg1 · h1. The infusion rate has an
influence on kinetics, but not dynamics. Age was a covariate for
LAG time.
CONVENTIONAL multicompartmental mammillary
pharmacokinetic models assume that drug added to the
central compartment is instantaneously completely
mixed and that this mixed plasma instantaneously ap-
pears in the arterial circulation. The failure of these
models to accurately predict the time course of arterial
drug concentration in the first minutes after administra-
tion is the result of this flawed assumption and has been
extensively described.1–6 Although a physiologically
based pharmacokinetic model may be considered an
accurate description of drug disposition from the start of
drug administration, difficulty in collecting the extensive
data for the model development and the fact that such
models are not readily fitted to clinical pharmacokinetic-
driven drug infusion caused by their complexity, have
limited their applicability into pharmacokinetic stud-
ies.5,7 More experimental approaches have been de-
scribed to reveal the delay between drug administration
and appearance of the drug at the site of arterial blood
sampling. Standard lag time models (LAG model), which
represent the time shift of dosing as if the drug was in
fact administered at a later time, and analytical solutions
of the TRANSIT compartment model (TRANSIT model),
which depicts a multiple-step process represented by a
chain of presystemic compartments and differs from the
LAG model by the presence of one additional parameter,
a transit rate constant, have been used by various au-
thors.8 Others have used more sophisticated recircula-
tory models to analyze arterial drug concentrations ver-
sus time using estimated cardiac output from the first
pass area under the curve in animal research.7
A first-order process, described by ke0, characterizes
the drug transfer between the plasma and effect site.9
When using a combined pharmacokinetic-dynamic
model to describe the complete dose-response relation-
ship, misspecification in the pharmacokinetic model
over the first few minutes will result in a less accurate
interpretation of the plasma effect-site equilibration.6
Induction dose, time course of drug concentration,
and drug effect of propofol are dependent on adminis-
tration rate. Therefore, the inclusion of dose rate into
kinetic-dynamic model in the early phase might optimize
the description of the time course of early drug disposi-
tion and drug effect.6,10
The aim of this study was to investigate if a com-
partmental model including LAG and TRANSIT models
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can describe the time course of arterial propofol con-
centration in the first minutes after administration
more accurately than a classic compartmental model.
We also studied the influence of the pharmacokinetic
model on the description of propofol’s cerebral drug
effect as measured by the Bispectral Index (BIS). In
addition, we aimed at investigating the influence of
propofol’s administration rate on these early phase
kinetics and dynamics.
Materials and Methods
Clinical Protocol
After securing local ethics committee (National De-
fense Medical College, Saitama, Japan) approval and writ-
ten informed consent, we enrolled 50 patients who were
American Society of Anesthesiologists physical status I or
II, aged 30–76 yr, and scheduled to undergo elective
gynecologic, orthopedic, or digestive surgery. Exclusion
criteria included body mass index greater than 30, neu-
rologic disorder, recent use of psychoactive medicine,
and significant heart, hepatic, or renal impairment.
All patients were randomly assigned to one of five
groups to receive 1.2 mg/kg propofol (1% Diprivan®;
AstraZeneca K.K., Osaka, Japan) given as continuous
infusion with the rate of 160, 80, 40, 20, or 10 mg · kg1 · h1
(group 1, 2, 3, 4, or 5, respectively). The continuous
infusions were administered by using a Graseby 3500
(Smiths Medical International, Watford, United Kingdom)
infusion pump. Age ( 65 and  65 yr) and gender were
stratified into all study groups.
Propofol was infused directly via an 18- or 20-gauge
catheter in a large forearm vein without any other fluids
given simultaneously. As such, the remaining dead space
was limited towards the dead space of the infusion
catheter (less than 0.023 ml) filled with blood before
starting the propofol administration. The propofol sy-
ringe and extension line were purged and pressurized
before being connected to the infusion catheter. The
moment the START button was pushed was considered
as time 0.
No other drugs were given during the study period. All
patients received 100% oxygen via a facemask during
the study period. When airway obstruction occurred,
airway was secured gently without any stimulation.
Sample Acquisition, Handling, and Processing
A 22-gauge arterial catheter was inserted in the radial
artery at the opposite site of the venous catheter for
propofol infusion.
To ensure accurate blood sample quality, a continuous
blood flow during the study period of around 50 ml/min
was generated by using a negative pressure blood draw-
ing device (Hemoquick®; Terumo, Tokyo, japan). Arte-
rial blood samples (1 ml each) were drawn by using
heparine-coated 2.5-ml syringes via a closed-system sam-
pling port at the arterial line (dead space 1.5 ml).
Arterial blood samples were taken at 10, 15, 20, 25, 30,
35, 40, 45, 50, 55, and 60 s during the first 1 min in all
groups. Samples were then collected every 10 s until
120, 150, or 200 s in groups 1, 2, and 3, respectively. In
group 4, samples were taken at 70, 80, 90, 120, 150, 180,
210, 220, 230, 240, 250, 260, 270, 280, 290, 300, and
310 s, and in group 5 at 70, 80, 90, 120, 150, 180, 210,
240, 300, 360, 420, 430, 440, 430, 440, 450, 460, 470,
480, 490, 500, 510, 520, and 530 s. These blood samples
were centrifuged within an hour of collection. The
plasma was transferred to polyethylene tube and kept at
–20°C until assayed.
Measuring Propofol Cerebral Drug Effect
Propofol cerebral drug effect was monitored by using
the BIS, which was derived from the frontal electroen-
cephalogram and calculated by the A-2000 BIS monitor
(version 4.0; Aspect Medical Systems, Norwood, MA) by
using the three BIS Sensor electrodes. The smoothening
rate of the BIS monitor was set at 15 s. BIS values range
from 100 to 0, with lower values denoting more drug
effect.11 The BIS values were recorded every 5 s by
Bispectrum Analyzer software developed by one of the
authors12 using an RS-232C connection between the BIS
monitor and a laptop computer. The end of the study
period was defined as 60 s after the end of last arterial
sampling time.
Drug Assay
Arterial plasma concentrations (Cp) of propofol were
determined by high-performance liquid chromatography
(RF-550, CTO-10AS, LC-10AD, SIL-10AD, SCL-10A, and
DGU-14A; Shimadsu, Kyoto, Japan) with fluorescence
detection at 310 nm after excitation at 276 nm.13 The
lower limits of detection and quantification were 1.7 and
5.6 ng/ml, respectively. Measured Cp below the lower
detection limit was not applied to the model develop-
ment and measured Cp between the lower limit of de-
tection and that of quantification was considered as the
half value of the lower quantification limit.
Population Pharmacokinetic Modeling
Basic Model Structure. The following structural mod-
els were evaluated; conventional 1-, 2-, and 3-compart-
mental models, conventional one-, two-, and three-com-
partmental models enlarged with LAG model,
conventional one-, two-, and three-compartmental mod-
els enlarged with a TRANSIT models, and conventional
one-, two-, and three-compartmental models enlarged
with a LAG and TRANSIT model (fig. 1). All compart-
mental models had a central compartment, and one or
two peripheral compartments, if necessary. The LAG
time and/or the TRANSIT model describes the time re-
quired for the venously injected drug to reach the sam-
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pling site of arterial blood. The ktr is a first-order transit
rate constant describing the movement of propofol be-
tween TRANSIT compartments or TRANSIT compartment
and central compartment in the TRANSIT model. The optimal
number of TRANSIT compartments was assessed by stepwise
addition or deletion of one TRANSIT compartment. All com-
binations of these models were compared.
All model parameters were estimated by using NONMEM
VI (GloboMax LLC, Hanover, MD). The interindividual
variability on each basic model parameter (V1, V2, V3,
CL1, CL2, CL3, ktr, and LAG time; V being the distribu-
tion volume for compartment, CL being the clearance
for the compartment) was estimated by using a log-
normal distribution:
iTV · e
i
where i is the parameter value in the i-th patient, TV is
the typical value of the parameter in the population, and
i is a random variable in the i-th patient with a mean of
0 and a variance of .2 Interindividual variability is re-
ported as , the SD of  in the log domain, which is
approximately the coefficient of variation in the standard
domain. Residual intraindividual variability was modeled
by using constant coefficient of variance model and
additive error model. The best model had the minimum
values of Bayesian Information Criterion among the all
evaluated model. These criteria were calculated by the
following equations:
Bayesian Information Criterion  OFV  K logN
where OFV is –2 log likelihood calculated as the objec-
tive function value (OFV) by NONMEM, K is the number
of parameter estimates in the model, and N is the sample
size of the data set. The Bayesian Information Criterion
value was used to select the best structural model be-
cause the Bayesian Information Criterion would provide
a more appropriate selection than the OFV when the
different structural models are compared.14
Covariate Assessment for Pharmacokinetic
Model. The best basic structural model was imple-
mented to assess the covariates by using a stepwise
forward addition and backward elimination approach. In
this process, a decrease in OFV by 7.88 (P  0.005,
chi-square test with 1 degree of freedom) was consid-
ered significant. When the assessed model included an
additional potential covariate without an increment of
the number of the parameter estimates, a decrease in
OFV was considered to obtain the potential covariate
into the final model. Weight, height, age, and dose rate
were assessed as potential covariates when the linear
regression analysis indicated significant correlation (P 
0.05) between a covariate and a parameter estimate.
After significant regression, all potential covariates
were tested on the parameters from the basic struc-
tural model (V1, V2, CL1, CL2, LAG, and ktr). Correla-
tions between mean transit time and model parame-
ters were also calculated to assess the accuracy of the
inclusion of LAG or ktr into the model:
mean transit time  LAG  Ntr ⁄ ktr
where Ntr is the number of transit compartments.
For assessing the effects of a covariate on the model
accuracy, we used not only OFV, but we also depicted
the measured/predicted Cp and measured Cp versus
time. When this figure indicated severe bias in the
assessed model, we excluded the model for further
consideration.
Population Pharmacodynamic Modeling
Basic Model Structure. The effect-site was assumed
to be linked to the plasma by a compartment with a
first-order equilibrium constant of ke0. A classic sigmoi-
dal maximum possible drug effect (Emax) model was
used for describing the relation between propofol effect-
site concentration (Ce) and the electroencephalographic
measures of propofol with either measured plasma con-
Fig. 1. Schema of the final two-compartmental pharmacokinetic model with a LAG time and six TRANSIT compartments (Ctr n).
The equilibration rate constants between central and peripheral compartments were calculated by using the following
equations: k12  Cl2/V1, k21  Cl2/V2. The elimination rate constant was calculated: k10  Cl1/V1. Cl1  clearance of central
compartment; Cl2  clearance of peripheral compartment; LAG time  the time shift of dosing as if the drug was in fact
administered to the pharmacokinetic model at a later time. TRANSIT compartments  a multiple-step process represented by
a chain of presystemic compartments; V1  distribution volume of central compartment, V2  distribution volume of peripheral
compartment.
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centration (Cp) or predicted Cp. The time course of the
predicted Cp was calculated during the pharmacody-
namic modeling by using the individual patients’ post
hoc Bayesian pharmacokinetic parameters estimated in
the pharmacokinetic modeling. The Ce with measured
Cp was calculated by using a “connect-the-dots” ap-
proach previously used by Schnider et al.15 and mathe-
matically described previously.6 The classic sigmoidal
Emax model is described by the following equation:
Effect  E0  (Emax  E0)
Ce
Ce50
 Ce
where Effect is the electroencephalographic effect (e.g.,
the measured BIS value), E0 is the baseline measurement
when no drug is present, Emax is the maximum possible
drug effect, Ce is the calculated effect-site concentration of
propofol, Ce50 is the Ce associated with 50% maximum
drug effect, and  is the steepness of the concentration
versus response relation. The model parameters were esti-
mated by using NONMEM. For Ce50, ke0, and , interindi-
vidual variability was permitted by using a log normal
distribution (i  TV · e
- i, which was the same equation
in the pharmacokinetic model). Interindividual vari-
ability for E0 was expressed by using a normal distri-
bution: i  TV  i. Interindividual variability is
reported as , the SD of  in the standard domain for
E0. Residual intraindividual variability was modeled by
using an additive error model.
In the pharmacodynamic modeling, we compared an
Emax model with a fixed Emax at zero and an Emax model
with an estimated Emax. Although one should be cautious
with extrapolations, these two pharmacodynamic mod-
els were studied as one might criticize that the BIS might
depict a maximum drug effect at a BIS value of zero. In
addition, we included the BIS delay, defined as a time
shift of applying the effect-site concentration to the
sigmoidal Emax model when BIS value and the effect-site
concentration were applied to the model, which reflects
the time delay for the BIS measurement. This delay is the
result of the combination of averaging algorithms (i.e.,
smoothening rate), the delay caused by the BIS signal qual-
ity and the delay in adaptation of one of artifact rejection
preprocessing steps.6,16 In this study, the BIS delay was
assessed as one value with no variation for all groups.
For the pharmacodynamic model approach, we as-
sumed that the underlying sigmoidal model that de-
scribes the relation between Ce and the drug effect is
not influenced by the dose rate of drug administration.
This is a fundamental assumption underlying the stan-
dard model of the effect-site. Therefore, we concurrently
estimated the model parameters for all five groups, only
permitting the value of ke0 to differ among groups.
Different Ke0 Values for the Basic Model. We as-
sessed the different ke0 for each basic structural model.
When one ke0 was determined for two or more groups,
each ke0 (different ke0) was used for each consecutive
group (e.g., one ke0 is for groups 1 and 2, and the other
ke0 is for groups 3, 4, and 5). The addition of ke0 was
considered statistically significant when the NONMEM
objective function value (OFV or –2 log likelihood) de-
creased by at least 6.63 for an additional ke0 (P  0.01,
chi-square test with one degree of freedom).
Covariate Assessment for the Pharmacodynamic
Model. After the assessment of the different ke0, the final
pharmacodynamic model was implemented to assess for
possible covariates. In this process, a significant correlation
(P  0.05) between a covariate and a parameter on the
linear regression and a decrease in OFV by 6.63 (P 0.01,
chi-square test with 1 degree of freedom) was an additional
criterion for a covariate. Schnider et al. reported that el-
derly patients are more sensitive to the hypnotic and elec-
troencephalogram effects of propofol than younger per-
sons.15 Therefore, age was explored as a covariate for Ce50.
Model Evaluation. For a basic internal evaluation of
the final pharmacokinetic model, a goodness-of-fit plot
was used. The plot included the correlation between
individual predicted concentrations by the Bayesian es-
timates and measured concentrations of propofol. We
also depicted measured/predicted Cp or measured/pre-
dicted BIS versus time that shows the bias of the predic-
tion versus time.
Bootstrap analysis was used for advanced internal evalu-
ation of both pharmacokinetic and dynamic final model.
One thousand bootstrap resampling data sets for both were
created by sampling data from the original data set with
replacement. Sample size of resampling data sets was the
same as that of original data set. The final pharmaco-
kinetic and dynamic model, including all significant
covariates, was fitted to each of the resulting data sets.
Confidence intervals of 95% were obtained for each
parameter estimate as the 25th and 97.5th percentiles.
Median absolute prediction error (MDAPE) and median
prediction error (MDPE) were also calculated as the
metrics of the accuracy by using the individual parame-
ters (population or post hoc Bayesian parameters) of the
Table 1. Demographic Data, Mean  SD (Range)
Group 1 Group 2 Group 3 Group 4 Group 5
Age, yr 54  8 (3766) 50  11 (4172) 58  7 (4969) 60  14 (3676) 59  14 (3075)
Gender, male/female 1/9 2/8 1/9 1/9 2/8
Weight, kg 60  5 (4865) 51  6 (3857) 52  7 (3961) 52  7 (4563) 57  7 (4669)
Height, cm 155  8 (138166) 153  9 (139164) 152  3 (148158) 157  5 (147163) 155  8 (146173)
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final model. For calculating these values, the following
equations were used.
Percentage prediction error (PE) of the predict-
ed CP:
PE 
measured Cp  predicted Cp
predicted Cp
	 100
Prediction error (PE) of the predicted BIS:
PE  measured BIS  predicted BIS
PE is an indication of the bias of the achieved concen-
trations, and the absolute value PE (PE) is a measure of
the precision (inaccuracy).
Fig. 2. Time course of measured and post
hoc Bayesian individual predicted arte-
rial plasma concentration (Cp) of propo-
fol for the five groups on the left and
right panels, respectively. Each patient
received propofol of 1.2 mg/kg with the
rate of 160, 80, 40, 20, or 10 mg · kg1 ·
h1 in group 1 (A, B), 2 (C, D), 3 (E, F), 4
(G, H), or 5 (I, J), respectively. Bold ver-
tical lines on the left panels show the
administration time of propofol.
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MDAPE indicates the inaccuracy of the Cp or BIS
predictions in the i-th subject:
MDAPEi  median PEij, j1, · · · , Ni
where Ni is the number of PE values obtained for the
i-th subject.
MDPE reflects the bias of the Cp or BIS predictions in
the i-th subject:
MDPEimedian  PEij, j1, · · · ,Ni
To illustrate the final pharmacokinetic model, espe-
cially for the effect of covariates, several simulations
were implemented.
Results
Pharmacokinetic Model Development
All recorded data were used. The airway was secured
with gentle jaw thrust in two patients, one in the group
4 and the other in group 5, because of airway obstruc-
tion. No patient experienced hemodynamic instability
during the study. The demographics for the patients in
the five groups are shown in table 1.
The left column in figure 2 shows the time course of
the measured Cp of propofol for the five groups, respec-
tively. There were no samples taken after 280 s for one
patient in group 4 and after 460 s for another patient in
group 5 due to a protocol violation. One sample at 70 s
in another patient in group 4 was not available because
of a technical problem with the sample line. No samples
revealed concentrations between the lower limit of de-
tection and that of quantification.
For the basic structural model, a two-compartmental
model enlarged with a LAG and TRANSIT model includ-
ing six TRANSIT compartments (fig. 1) was selected as
the best basic model (table 2). Linear regression analysis
indicated several potential covariates, including dose
rate for LAG and ktr. After the visual inspection of the
correlation between dose rate and mean transit time (fig.
3), we decided to test these covariates for the final model.
All covariates were examined for their potential linear re-
lationship with the structural pharmacokinetic parameters
(see table, Supplemental Digital Content 1, which lists
OFVs for the examined models including potential co-
variates, http://links.lww.com/ALN/A548). The best
model includes dose rate for ktr, age for LAG time, and
weight for V1 as covariates (fig. 1; see also table, Supple-
mental Digital Content 2, which shows the NONMEM
representation of the final pharmacokinetic model,
http://links.lww.com/ALN/A549). The parameter esti-
mates in our final pharmacokinetic model are repre-
sented in table 3. Time courses of post hoc Bayesian
predicted concentration for all patients are shown on
the right column in figure 2.
Model Evaluation for the Final Pharmacokinetic
Model
Figure 4 represents the goodness-of-fit plot for the
measured plasma concentrations versus both population
and post hoc Bayesian predicted concentrations (fig. 4A
and 4B for the all groups; see also figures, Supplemental
Digital Content 3, which include the goodness-of-fit
plots for each group, http://links.lww.com/ALN/A550),
and the time course of the measured/predicted Cp versus
time (fig. 4C–F for all groups; see also figures, Supplemental
Digital Content 3, which include the time course for each
group, http://links.lww.com/ALN/A550). These figures in-
dicate that the model provided an accurate description
of the observed data. The sampling point where mea-
sured and/or predicted Cp was below quantification
limit of the drug assay was excluded from figure 4C–F
(see figures, Supplemental Digital Content 4, which de-
pict the detailed information for the below limit of quan-
tification values, http://links.lww.com/ALN/A551). On
the final population model, the predicted plasma con-
centrations showed larger variability in the first minute
than that in the later time (fig. 4E).
One thousand bootstrap runs were obtained with the
same sample point at the calculating estimates of the
Table 2. The Bayesian Information Criterion for the Basic
Structural Pharmacokinetic Models
Number of Disposition
Compartments LAG Model
Number of Transit
Compartments
Bayesian Information
Criterion
1  0 15,755
2  0 *
3  0 *
1  0 14,744
2  0 14,363
3  0 14,369
1  30 14,891
2  30 14,344
3  30 14,320
1  6 14,723
2  6 14,157
3  6 14,159
* The measured plasma concentrations could not be fitted on the correspond-
ing basic pharmacokinetic model because several parameters were esti-
mated as infinitesimal or infinite. The lower value of the Bayesian Information
Criterion indicates the better fit.
Fig. 3. Plot of the dose rate versus the mean transit time calcu-
lated as LAG time 6/ktr (ktr transit rate constant for TRANSIT
compartments) by using post hoc Bayesian individual parame-
ter estimates.
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final model. The number of successfully converged resa-
mples was 798. Confidence intervals of 95% for param-
eter estimates are shown in table 3. The intervals for
thetas exclude zero values. These results revealed that all
the final estimated model parameters have acceptable typ-
ical values. MDAPE and MDPE of the final pharmacokinetic
model were 23.6% and –1.4%, and 8.9% and 0.8% for
population and post hoc prediction, respectively. These
metrics indicated an acceptable bias and accuracy of the
model.
Simulations with the Final Pharmacokinetic Model
We performed several simulations to show the influ-
ence of the covariates applied our final model as
shown in figure 5. The influence of dose rate on the
initial time course of the propofol arterial concentra-
tion as predicted by the final model is shown in figure
5B for a typical patient. Lower infusion rate results in
longer time between the start of infusion and the start
of increasing predicted concentration than faster in-
fusion rate as transit rate constant (ktr) also produces
lag time (fig. 5B). For a typical patient, the influence of
age and weight on the time course of the predicted
arterial propofol concentration is plotted in figures 5D
and 5F, respectively.
Pharmacodynamic Model Development
Five patients (one each in groups 1, 2, and 4 and two
in group 5) were excluded because of technical prob-
lems with the BIS recordings (automatic recheck of the
BIS monitor during the study period due to insufficient
sensor fitting). Therefore, 45 patients were included into
the pharmacodynamic analysis.
After initial attempts, we decided to use the post hoc
Bayesian individual predicted Cp for the pharmacody-
namic examinations because NONMEM failed to calcu-
late the converged estimates with measured Cp. Apply-
ing multiple ke0 values into the model for different
administration rates did not improve the model (see table,
Supplemental Digital Content 5, which represents OFVs for
the different ke0, http://links.lww.com/ALN/A552). Age
was not included into the pharmacodynamic model be-
cause R square values between age and the post hoc ke0
value for the models including estimated Emax or fixed Emax
at zero indicated no significance (R2  0.001 or 0.039,
respectively).
Final Pharmacodynamic Model
The parameter estimates in our final pharmacody-
namic model including estimated or fixed Emax are
shown in tables 4 and 5, respectively (see table, Sup-
plemental Digital Content 6, which is the NONMEM
representation of the final pharmacodynamic model,
http://links.lww.com/ALN/A553). Interindividual vari-
ability is expressed as SD for E0 and coefficient of varia-
tion for Emax, Ce50, and . The ke0 values were 0.414
min1 or 0.404 min1 for the model including estimated
or fixed Emax, respectively. The LAG times for BIS delay
corresponding to the effect-site concentration were 19.7 or
20.3 s for the models including estimated or fixed Emax,
respectively. Figure 6 shows the measured BIS and post hoc
individual Ce versus time, and the relation between the BIS
values and the post hoc individual predicted Ce of propofol.
The sigmoid curves of the sigmoidal Emax model for the
two final models indicates the similar relation between
Ce and BIS when BIS value is more than 45 (fig. 7).
Table 3. Pharmacokinetic Parameters for the Final Model
Model Parameter Value
Interindividual Variability
CV 95% CI
V1, l Weight [kg] · 1 19.3% 130.4%
V2, l 2 53.2% 39.265.0%
Cl1, l/min 3 25.3% 20.828.9%
Cl2, l/min 4 48.6% 37.356.9%
LAG time, s Age [yr] · 5 41.4% 32.048.8%
ktr, /min 6  (DR  345) · 7 35.9% 27.242.8%
Parameter Estimate SEM 95% CI for Estimate
1 0.0104 0.00180 0.006190.0136
2 2.20 0.114 2.022.45
3 3.20 0.0777 3.043.34
4 4.21 0.317 3.614.84
5 0.399 0.0153 0.3700.431
6 29.2 2.44 25.034.6
7 0.0471 0.00789 0.03460.0624
Intraindividual Variability 95% CI

1 [%] 15.1 14.215.8%

2 [ng/ml] 37.9 17.952.8
CI  confidence interval; Cl1  clearance of central compartment; Cl2  clearance of peripheral compartment; CV  coefficient of variation calculated as
(exp(2)-1)0.5 of the variances of the corresponding ; DR  dose rate (ml/h) for 1% propofol; ktr  transit rate constant; LAG time  the time shift of dosing as
if the drug was in fact administered to the pharmacokinetic model at a later time; V1  distribution volume of central compartment; V2  distribution volume of
peripheral compartment; 
1 and 
2  the variances of interindividual variability for constant coefficient of variance model and additive error model, respectively.
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Pharmacodynamic Model Evaluation
For both pharmacodynamic models, figures 8A–8D show
the goodness-of-fit plot for the time course of the mea-
sured/predicted BIS versus time. Figure 8E and 8F depict
the sigmoid curve and all measured BIS value versus post
hoc individual Ce. These figures indicate that the model
provided an accurate description of the observed data.
One thousand bootstrap runs were obtained with the
same sample point at the calculating estimates of the two
final models. The numbers of successfully converged
resamples were 891 or 904 for the models including
estimated Emax or fixed Emax at zero, respectively. Con-
fidence intervals of 95% for parameter estimates are
shown in tables 4 and 5 for the two final pharmacody-
namic models. These results revealed that all the final
estimated model parameters have acceptable typical
values. The MADPE and MDPE values of the two final
pharmacodynamic models are shown in table 6 for
both population and post hoc predictions. These met-
rics indicated an acceptable bias and accuracy of the
model.
Correlation between Dose Rate and ke0
Figure 9 shows the post hoc ke0 values versus the dose
rate of propofol in the final pharmacodynamic model.
There were no significant differences among the groups
using a Tukey multiple comparison test.
Discussion
We found that a multi-compartmental model including
a LAG time and TRANSIT model described the time
course of arterial propofol concentration in the first
minutes after administration more accurately than a clas-
sic compartmental model. In addition, we found that the
propofol administration rate influenced the early phase
kinetics but not the dynamics. Age and weight were also
defined as covariates in our pharmacokinetic model.
Pharmacokinetics
Conventional mammillary multi-compartment pharma-
cokinetic models for propofol are well accepted and
form the basis for clinically applied target-controlled
infusion systems. Unfortunately, these classic models
insufficiently predict the time course of the arterial
propofol drug concentration for the first minutes of drug
administration.6 The failure of these models is an ex-
pected consequence of a flawed assumption with con-
ventional mammillary compartmental models of instan-
taneous mixing in the central compartment and
immediate appearance of drug at the arterial sample
side. More appropriate models are required to study the
early phase kinetics, certainly in relation to possible
covariates influencing these kinetics.
Before being able to analyze the influence of covariates
such as the infusion rate on the dose-response of propo-
fol, we needed the model including the delay between
drug administration and appearance of the drug at the
site of arterial blood sampling. Although we realized that
this delay might be explained mechanistically or by phys-
iologic phenomena such as transit delay due to passage
through the forearm vein17 and lungs,18 it was only our
intention to model the delay by using a compartmental,
mathematical approach. The LAG time and TRANSIT
models were previously used to describe the absorption
delay in orally given drugs.8 Upton et al. also used the
concept of LAG time in their physiologically based
model to describe the delay between the infusion site
and the vascular mixing volume submodel and a TRANSIT
model with three compartments in the lung submodel.18
The recirculatory model by Avram and Krejcie also in-
cludes the chain of TRANSIT compartments for the cen-
tral circulation in the model.7 We assessed four basic
structural models combining a conventional one-, two-,
and three-compartmental model enlarged with the LAG
time and/or TRANSIT model in an attempt to increase
the accuracy of the traditional compartmental model for
describing the time course of the propofol arterial con-
centration, especially during the first minutes of drug
administration. We revealed that both LAG and TRANSIT
Fig. 4. Plots of the propofol predicted concentrations by popu-
lation estimates (A) and the individual post hoc Bayesian esti-
mates (B) of the final pharmacokinetic model versus measured
concentrations (Cp). Measured/predicted Cp versus time for (C)
population and (D) individual. Measured/predicted Cp versus
time in the first 1 min using the wide scale of Y-axis compared
with C and D for (E) population and (F) individual.
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compartments were required to describe our data accu-
rately. We did not apply a physiologic model to depict
the early drug disposition of propofol because this is
much more complex and was not required to solve our
hypothesis. However, we tried to add a recirculatory
step to our compartmental model, similar to the work of
Avram and Krecjie7; however, this did not result in a
more accurate model when using our database (see fig-
ure, Supplemental Digital Content 7, which represents
the examined compartmental model with recirculation-
like characteristics, http://links.lww.com/ALN/A554).
The final structural model was a two-compartmental
model enlarged with a LAG time and TRANSIT model.
Although most previously published conventional com-
partmental pharmacokinetic models of propofol have three
compartments,19–21 our best basic model includes only
two disposition compartments. This is because we focused
on the first ten minutes to describe the early phase kinetics,
especially in the first minutes. This was a study in patients,
so it was considered unethical to draw more blood samples
at a later time point. Thus, the time course of measured
concentration of propofol excluded the information for
Fig. 5. Simulation with the final pharma-
cokinetic model and influence of covari-
ate on model parameter: (A) influence of
dose rate on transit rate constant (ktr),
(B) dose rate on ktr for 50-yr-old, 60-kg
subject with 1,000, 250, and 50 ml/h in-
fusion of 1% propofol, (C) influence of
age on LAG time, (D) age on LAG time and
for 60-kg subject with 400 ml/h infusion,
(E) influence of weight on V1, (F) weight
on distribution volume of central com-
partment (V1) for 50-yr-old subject with
2-min 60 mg · kg1 · h1 infusion (dose is
2 mg/kg). Cp  plasma concentration;
LAG time  the time shift of dosing as if
the drug was in fact administered to the
pharmacokinetic model at a later time.
Table 4. Pharmacodynamic Parameters for the Final Model, When Estimating Emax
Model Parameter Estimate (95% CI) SEM
Interindividual Variability*
SD or CV [%] (95% CI)
E0 94.1 (93.394.8) 0.391 3.59 (2.774.17)
Emax 38.7 (32.540.5) 1.92 N/A
Ce50, g/ml 2.92 (2.613.28) 0.172 41.2% (27.752.5%)
 4.20 (2.985.65) 0.690 130% (94.5166%)
ke0, /min 0.414 (0.3230.521) 0.0518 92.1% (67.1133%)
Lag time for BIS delay, s 19.7 (12.727.6) 3.72 N/A
Intraindividual variability 3.89 (3.464.23)†
BIS  bispectral index; Ce50  effect-site concentration associated with 50% maximal drug effect; CI  confidence interval; CV  coefficient of variation
calculated as (exp(
2)-1)0.5 of the corresponding ; where 
 is variance for the corresponding ; E0  baseline measurement of BIS when no drug is present;
Emax  maximum possible drug effect; ke0  equilibrium constant between plasma and effect-site; N/A  not applicable;   steepness of the concentration-
versus-response relation.
* Interindividual variability is expressed as SD for E0, and CV for Emax, Ce50, and ; † SD (95% CI).
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-phase, where half-life is over 4 h.22 We have to accept that
we only studied the early disposition of propofol; as such, our
pharmacokinetic model should not be extrapolated to predict
the pharmacokinetic behavior of propofol at a later stage.
Covariate analysis started by investigating the influ-
ence of dose rate on the early phase kinetics. Ktr was
influenced by dose rate as shown in table 3 and depicted
in figure 5. Several other covariates were tested and
Table 5. Pharmacodynamic Parameters for the Final Model, When Using Fixed Emax at Zero
Model Parameter Estimate (95% CI) SEM
Interindividual Variability*
SD or CV [%] (95% CI)
E0 94.7 (94.095.5) 0.393 3.61 (2.614.22)
Emax 0 N/A N/A
Ce50, g/ml 4.55 (3.465.43) 0.499 56.4% (37.373.6%)
 2.44 (1.903.54) 0.429 108% (71.9143%)
ke0, /min 0.404 (0.2780.550) 0.0680 101% (63.1167%)
Lag time for BIS delay, s 20.3 (6.9928.3) 5.76 N/A
Intraindividual variability 4.11 (3.614.58)†
BIS  bispectral index; Ce50  effect-site concentration associated with 50% maximal drug effect; CI  confidence interval; CV  coefficient of variation calculated
as (exp(
2)-1)0.5 of the corresponding , where 
 is variance for the corresponding ; E0  baseline measurement of BIS when no drug is present; Emax  maximum
possible drug effect; ke0  equilibrium constant between plasma and effect-site; N/A  not applicable;   steepness of the concentration-versus-response relation.
* Interindividual variability is expressed as SD for E0, and CV for Emax, Ce50, and ; † SD (95% CI).
Fig. 6. Results from the final pharmacodynamic model, including estimated maximum possible drug effect (Emax) (first column) or
fixed Emax at zero (third column). Individual measured Bispectral Index (BIS) values and the post hoc Bayesian individual effect-site
concentration (Ce) versus time (first column and the third column, respectively). The second column and fourth column show the
BIS versus post hoc Ce. Each patient received propofol of 1.2 mg/kg with the rate of 160, 80, 40, 20, or 10 mg  kg1  h1 in group
1 (A–D), 2 (E–H), 3 (I–L), 4 (M–P), or 5 (Q–T), respectively.
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resulted in a final model, including age as a covariate for
the LAG time and weight for V1 (fig. 5). Other tested
covariates didn’t improve our model.
These findings are consistent with the results from He
et al.,23 who reported that the time before propofol or
indocyanine green emerges from the central vein was
approximately 13 s, despite the difference of the sam-
pling site and when taking into account our more sensi-
tive lower limits of detections of propofol (50 or 1.7
ng/ml, respectively). The age distribution of our study
population allowed us to test the influence of age on the
propofol early phase kinetics. We found that the LAG
time increased in older patients, as shown in figure 5.
Although one may consider that lower cardiac output
increased LAG time in older patients, there was no cor-
relation between LAG time and cardiac output by using
our data (see figures, Supplemental Digital Content 8,
which show the relation between measured cardiac out-
put and two model parameters of LAG time and transit
rate constant, http://links.lww.com/ALN/A555). Others
also found an influence of age on the propofol drug
disposition, even when using classic multi-compartmen-
tal model without coverage of the early phase kinetics.20
Fig. 7. Curves of the final sigmoidal maximum possible drug
effect (Emax) models. Bold line and dotted line show the curve
for estimated Emax and fixed Emax at zero, respectively. BIS 
Bispectral Index; Ce  effect-site concentration.
Fig. 8. Plots for the evaluation of the final
pharmacodynamic model including esti-
mated maximum possible drug effect
(Emax) (left panels) or fixed Emax at zero
(right panels). Measured/predicted
Bispectral Index (BIS) versus time is
shown for population (A, B) and post hoc
Bayesian individual (C, D) models. (E and
F) Measured BIS versus post hoc effect-
site concentration (Ce).
Table 6. Prediction Error for Bispectral Index Calculated as
Difference between Measured and Predicted Values of the
Final Pharmacodynamic Model
Prediction Error
Estimated Emax  38.7
Prediction Error
Fixed Emax  0
Population
Median absolute 5.9 6.2
Median 2.2 -0.1
Post Hoc
Median absolute 1.8 1.6
Median 0.2 0.2
Emax  maximum possible drug effect.
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As shown in table 3, V1 of 0.0104 l/kg is smaller than
observed by others.19–21 When using conventional com-
partmental models, the central volume of distribution is
dependent on the time of blood sampling and will ex-
pand with time. As such, with earlier blood sampling,
one will obtain smaller central volumes. However, con-
ventional compartmental models usually overestimate
the central compartmental volume because they ignore
the complexity of delay caused by intravascular mixing.7
Weight was considered as a covariate for V1. As the
covariate analysis is fully dependent on the study popu-
lation, one should be careful when comparing models
from propofol because different populations might re-
sult in different model-dependent covariates.
We tested the internal validity of our model by using
several analyses. As shown in figure 4, the population
measured/predicted Cp versus time revealed the initial
large variability in the population. The model bias is
within acceptable limits. In addition, very large variabil-
ity is observed over the first minute after the start of
propofol administration, which may be partially caused
by the variability of transit time from infusion site to
sampling site (fig. 4C and 4E). This result indicated that
our final population model was not able to address the
variability in the first minute, although the high-resolu-
tion arterial samples were taken. The individual post hoc
Bayesian propofol Cp are accurately described by the
model. Figure 4 also depicts a good correlation between
the individual post hoc Bayesian predicted arterial con-
centration and measured arterial concentration. As
shown in table 3, the 95% confidence intervals of the
parameter estimates for our model calculated by the
bootstrap analysis exclude zero, revealing the accuracy
of the model. In addition, all parameter estimates calcu-
lated by NONMEM are similar to the median of the
estimates calculated by bootstrap analysis (data are not
shown). The MDAPE and MDPE demonstrate that the bias
and the predictive inaccuracy are low for both population
and individual post hoc Bayesian estimates. A model is
expected to be accurate if the typical value of the predic-
tive inaccuracy is less than 25%.21 Our results indicate that
our final pharmacokinetic model has an acceptable accu-
racy and is in the range of previous publications.21,24,25
Pharmacodynamics
The propofol cerebral drug effect was measured by
using BIS, as applied in various previous studies.6,26 Our
pharmacodynamics could be described by using a classic
sigmoid Emax model. As shown in figure 6, our propofol
dosing strategy resulted in a significant decrease in BIS
values in all groups. However, we didn’t obtain BIS levels
lower than 25. As such, the typical value for Emax in our
model was 38.7. As one might criticize that we know
that the BIS can go down to zero, we developed a second
model fixing the Emax at zero. Although we accept the
danger of extrapolation, figure 7 shows that both models
behaved similarly above a BIS value of 45. For both
pharmacodynamic models, acceptable population and
post hoc Bayesian estimation were reached as proven by
the accurate measured/predicted BIS values (fig. 8),
bootstrap analysis, and MDAPE and MDPE (table 6).
When analyzing the raw data, a certain delay in the BIS
behavior might be observed. This delay may reflect the
combination of the averaging algorithm to calculate the
BIS and the delay in adaptation of one of the artifact
rejection processing steps.6 To take care of these delays,
we included a BIS delay into our modeling work. Under
accurate signal quality conditions, the average delay can
in theory be estimated around 10 and 15 s. We found a
typical BIS delay of 19.7 s or 20.3 s when applying the
model with the estimated or the fixed Emax, which
comes slightly longer than the theoretical delay. Ke0
values were also similar between two pharmacodynamic
models (table 4 and 5). This similarity among the models
illustrated a potential of extrapolation on the model
including fixed Emax at zero. However, one should be
cautious with the possible lack of uniformity across the
BIS between 100 and 0, as shown by Kreuer et al.27
To develop the pharmacodynamic model, we used the
traditional two-step described by Sheiner et al. approach
for the pharmacodynamic modeling.9 The two-step ap-
proach is preferred in pharmacokinetics-pharmacodynam-
ics modeling because a large number of post hoc parameter
estimates causes the uncertainly to calculate the parameter
estimates when one develops a pharmacokinetic and a
pharmacodynamic model simultaneously.
Propofol transfer between the plasma and effect-site
can be modeled as a first-order process characterized by
ke0.
9,28 The standard model of ke0 assumes that the rate
of equilibration between the plasma and the site of drug
effect is independent of the rate of drug administration;
however, to the best of our knowledge, scientific valida-
Fig. 9. Post hoc transit rate constant (ke0) values versus the dose
rate of propofol in the final pharmacodynamic model including
estimated maximum possible drug effect (Emax) (A) or fixed
Emax at zero (B).
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tion for propofol is still incomplete. Doufas et al. found
that induction speed is not a determinant of propofol
pharmacodynamics. In their study, they applied a com-
bined pharmacokinetic-dynamic model, whereby the
pharmacokinetics were described by using a classic
pharmacokinetic model. Classic pharmacokinetic mod-
els do not describe the early phase kinetics accurately;
therefore, the misspecification in the pharmacokinetic
model over the first few minutes might have influenced
their findings.6
We studied whether a real influence of the propofol
administration rate on ke0 exists. As such, we aimed at
studying the influence of the administration rate on the
propofol plasma-effect site equilibration using the accu-
rate individual post hoc Bayesian predicted plasma con-
centration based on the enlarged pharmacokinetic
model describing the early phase kinetics. We hereby
focused on that range of infusion rates up to 1,200 ml/h
available in clinically applied syringe pumps. Our final
model applied one ke0 value for administration rates
between 10 and 160 mg · kg  1 · h  1, hereby covering
the infusion rates available in commercial syringe
pumps. As such, our results suggest that a model with
only one ke0 is appropriate and can be applied during
target-controlled infusion. Our conclusion that ke0 is
independent from dose rate is also confirmed in figure 9,
which depicts the relation between dose rates and the
patient individual ke0s. Of course, one must be careful to
not extrapolate our conclusions to models including
very fast bolus administration. In these manually admin-
istered bolus injections, multiple ke0s might be appro-
priate as found previously.6
In conclusion, we found that a combined pharmacoki-
netic-dynamic model consisted of a two-compartmental
model with a LAG time and TRANSIT compartments to
describe the kinetics and a sigmoid Emax model with BIS
delay to describe the dynamics is accurate and takes care
of the early phase pharmacology of propofol during
infusion rate between 10 and 160 mg · kg1 · h1.
Kinetics and dynamics could be connected with a sin-
gular ke0 not influenced by the propofol infusion rate.
However, the early phase kinetics of propofol were
influenced by the infusion rate; as such, dose rate was
included as a covariate for ktr. LAG time was influenced
by age. In addition, although our modeling was able to
handle the early phase pharmacokinetics, the large vari-
ability of population predicted plasma concentration in
the first 1 min after the start of propofol infusion sug-
gested that there may be a limit to how much pharma-
cokinetic models can predict the plasma concentrations
against large variability of plasma concentration.
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